Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2026)
Beam Therapeutics (BEAM) reported Free Cash Flow of -$130.7 million for Q1 2026, down 24.12% year-over-year from -$172.3 million in Q1 2025, and down 60.55% quarter-over-quarter from -$81.4 million in Q4 2025.
Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Free Cash Flow data on file, last reported at -$130.7 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$130.7 million, down 24.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$371.8 million (down 5.23% YoY), and the FY2025 annual result was -$346.4 million, changed 0.49% from the prior year.
- Free Cash Flow declined to -$130.7 million in Q1 2026 per BEAM's latest filing, from -$81.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $211.2 million in Q1 2022 and troughed at -$130.7 million in Q1 2026.
- A 5-year average of -$60.9 million and a median of -$83.2 million in 2024 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 521.99% in 2022 and fell as far as 532.5% in 2022.
- A 5-year view of Free Cash Flow shows it stood at -$112.5 million in 2022, then jumped by 216.89% to $131.5 million in 2023, then slumped by 154.17% to -$71.2 million in 2024, then dropped by 14.34% to -$81.4 million in 2025, then tumbled by 60.55% to -$130.7 million in 2026.
- Business Quant data shows BEAM's Free Cash Flow at -$130.7 million in Q1 2026, -$81.4 million in Q4 2025, and -$78.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -130.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130.75 Mn |
| Mar 31, 2026 | -130.75 Mn |
| Dec 31, 2025 | -81.43 Mn |
| Dec 31, 2025 | -81.43 Mn |
| Sep 30, 2025 | -78.40 Mn |
| Sep 30, 2025 | -78.40 Mn |
| Jun 30, 2025 | -81.20 Mn |
| Jun 30, 2025 | -81.20 Mn |
| Mar 31, 2025 | -105.34 Mn |
| Mar 31, 2025 | -105.34 Mn |
| Dec 31, 2024 | -71.22 Mn |
| Dec 31, 2024 | -71.22 Mn |
| Sep 30, 2024 | -93.58 Mn |
| Sep 30, 2024 | -93.58 Mn |
| Jun 30, 2024 | -83.17 Mn |
| Jun 30, 2024 | -83.17 Mn |
| Mar 31, 2024 | -100.11 Mn |
| Mar 31, 2024 | -100.11 Mn |
| Dec 31, 2023 | 131.48 Mn |
| Dec 31, 2023 | 131.48 Mn |